KLRK1 and acute myeloid leukemia: Here, we examined CC-96191, a “TriNKET” protein drug that binds CD33 on AML cells at the same time it binds two different proteins, CD16a and NKG2D, on natural killer (NK) cells, thereby activating these immune cells and engaging them to kill AML cells.